Global Ophthalmic Steroids Drug Market Size, Share and Trends Analysis Report, By Type (Uveitis, Diabetic Macular Edema, Allergic Conjunctivitis, Keratitis, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global ophthalmic steroids drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ophthalmic steroids are medicines that mainly contain corticosteroids. It is used to provide relief from inflammation and symptoms such as swelling, pain, redness, or irritation of the eyes. The major factor expected to drive the market is the rising prevalence of intra ocular eye disorders such as age-related macular degeneration (AMD), diabetic retinopathy, dry eye syndrome, among others, especially in elderly people. In addition, an increase in the prevalence of diabetes mellitus may lead to diabetes retinopathy that is driving the demand for ophthalmic steroids drug.

Furthermore, the increase in the geriatric population, rise in prevalence of eye diseases such as glaucoma, cataract, and macular degeneration, a surge in demand for ophthalmic drugs, and the increase in investment in R&D activities by various healthcare companies will propel the growth of global ophthalmic steroids drug market during the forecast period. Several initiatives taken by the government for the development and manufacturing of different combinations of ophthalmic drugs are further boosting the growth of the global ophthalmic steroids drug market during the forecast period.

Some major players in the market include Bausch & Lomb, Inc., Allergan plc, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, Ocular Therapeutix, Inc. announced that the company received the US Food and Drug Administration (USFDA) approval for the Supplemental New Drug Application (sNDA) to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. The company added that DEXTENZA is the first, FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Bausch & Lomb, Inc., Allergan plc, and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ophthalmic Steroids Drug Market Report by Segment

By Type

• Uveitis
• Diabetic Macular Edema
• Allergic Conjunctivitis
• Keratitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Ophthalmic Steroids Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa